Solid tumor associated with an acquired peripheral neuropathy

Solid tumor associated with an acquired peripheral neuropathy is a paraneoplastic neurological condition in which the presence of a solid tumor (such as lung, breast, ovarian, or other carcinomas) triggers an immune-mediated peripheral neuropathy. This is not a primary genetic disorder but rather an acquired condition where the body's immune response against the tumor cross-reacts with components of the peripheral nervous system. The condition falls under the broader category of paraneoplastic neurological syndromes. Patients may develop sensory neuropathy, sensorimotor neuropathy, or autonomic neuropathy, often preceding the diagnosis of the underlying malignancy. Key symptoms include numbness, tingling, burning pain, weakness in the extremities, loss of reflexes, difficulty with balance and coordination, and in some cases autonomic dysfunction such as orthostatic hypotension or gastrointestinal dysmotility. The neuropathy can be subacute or chronic in onset and may be severely disabling. Anti-neuronal antibodies (such as anti-Hu/ANNA-1, anti-CV2/CRMP5, or anti-amphiphysin antibodies) are frequently detected and support the paraneoplastic diagnosis. Treatment focuses on addressing the underlying solid tumor through surgery, chemotherapy, or radiation, which may stabilize or improve the neurological symptoms. Immunomodulatory therapies including intravenous immunoglobulin (IVIg), plasma exchange, or corticosteroids may be used, though response is variable. Symptomatic management of neuropathic pain with medications such as gabapentin or pregabalin is also an important component of care. Early identification and treatment of the underlying malignancy offers the best chance of neurological improvement.

Common questions about Solid tumor associated with an acquired peripheral neuropathy